At our site, we currently have another double-blind, randomized trial (VEK no. H-18036500) ongoing to investigate whether SimeCOS can reduce musculoskeletal side effects, such as arthralgia and myalgia, in breast cancer patients receiving adjuvant aromatase inhibitor therapy after surgery. This evidence concerns the gene CYP19A1 and breast carcinoma.